Phaseline

Targets › KAT6

KAT6: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: the race on KAT6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Stemline TherapeuticsMEN2312
KAT6 inhibitor
KAT6Phase 1Advanced Breast CancerOct 2027
IDEAYA BiosciencesIDE574
KAT6/KAT7 co-inhibitor
KAT6, KAT7Phase 1CancerDec 2029

Conditions

Cancer (1) Advanced Breast Cancer (1)

Modalities

small molecule (2)

Companies

IDEAYA Biosciences (1) Stemline Therapeutics (1)

Related targets

KAT7 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.